Rate My Professor James Lindsay

Professor Lindsay's research centers on translational mucosal immunology in IBD, encompassing leukocyte trafficking, monocyte and macrophage differentiation, and fibrosis control. He is Chief Investigator for multiple IBD clinical trials, including the NIHR-funded ASTIClite trial evaluating low-intensity autologous haematopoietic stem cell transplantation for refractory Crohn’s disease. His contributions include leadership on the British Society of Gastroenterology IBD Clinical Trials Steering Group. Previously, he held positions as Education Officer and Governing Board member of the European Crohn’s and Colitis Organisation (ECCO), ECCO e-learning ambassador, and chair of the ECCO Education Committee. He chaired ECCO working groups developing consensus guidelines on Crohn’s disease and ulcerative colitis management and is a member of the International Organisation of IBD (IOIBD). Key publications feature the 'UK guideline on transition of adolescent and young persons with chronic digestive diseases from paediatric to adult care' (Gut, 2017), analyses of long-term safety of upadacitinib in IBD (Clinical Gastroenterology and Hepatology, 2026), and studies on stem cell transplantation efficacy in Crohn’s disease (JAMA, 2015), alongside extensive outputs in Journal of Crohn’s and Colitis and other premier journals.